Tag
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.
Five-year data from the ULTIMATE I and II open-label extension demonstrate that ublituximab maintains exceptionally low relapse rates and slows disability progression in relapsing multiple sclerosis, emphasizing the clinical superiority of
The international NEOS2 study validates a refined clinical score using five baseline variables to accurately predict short-term immunotherapy response, one-year functional status, and three-year return to work or school in patients with ant
The NEOS2 score, an updated clinical tool, accurately predicts treatment response, one-year functional status, and three-year work/school resumption in anti-NMDAR encephalitis patients, offering clinicians a robust framework for early treat
The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w
A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.
